MediGene AG · LS:A40ESG
MediGene — Investor Presentation (April 2021)
26 slides from MediGene's investor presentation, April 2021
Slide 1: Building next generation TCR-T cell therapies for solid cancers
Building next generation TCR-T cell therapies for solid cancers Medigene Corporate Presentation, April 2021 1
Slide 2: Forward looking statements disclaimer
Forward looking statements disclaimer All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to,
Slide 3: Investment highlights
Investment highlights Powerful platform to develop best-in-class T cell-based immunotherapies for solid tumors Cutting edge ability to select optimal T cell receptors Optimal TCR properties: Higher avidity & specificity Strength in screening healthy TCR repertoires: Improved safety Collection of TCR
Slide 4: Key information
Key information Company Listing Martinsried, near Munich, Germany Frankfurt Stock Exchange (MDG1) ~80 employees ~24.6 m shares outstanding ~€30.0m cash* ~€98 m market cap** COVID-19 Situation Update Outlook Personnel TCR discovery against novel antigens progressing Work from home and on-site (UdeM/I
Slide 5: Discovery platform identifies best-in-class TCRs for solid tumors
Discovery platform identifies “best-in-class” TCRs for solid tumors Discovery of optimal affinity TCRs Tumor brings excellence to the development of TCR-T cell TCR-T products for solid tumors TCR-T Automated high-throughput platform industrializes rapid isolation of non- mutated high-affinity TCRs “
Slide 6: TCR approach: more targets, greater sensitivity than CAR-T
TCR approach: more targets, greater sensitivity than CAR-T • Human leukocyte antigens (HLAs) come in different classes and subtypes which are inherited and show the immune system peptides from within cells • TCRs on T cells interact with HLA- peptide complexes on tumor cells to determine which cells
Slide 7: Pipeline: A platform for excellence in solid tumors
Pipeline: A platform for excellence in solid tumors Project Target Preclinical Phase I Phase II Partner AML, MDS MDG1011 TBD (PRAME) Solid tumors MDG10XX TCR-T (undisclosed) Undisclosed bluebird bio (MAGE-A4) Multiple myeloma, Cytovant solid tumors (CVT-TCR-01) (NY-ESO-1) AML DC vaccine TBD (WT-1 /
Slide 8: Platform to identify optimal T cell receptors
medigene Platform to identify optimal T cell receptors
Slide 9: TCR discovery engine: Non-mutated, safer TCRs via high-throughput automation
TCR discovery engine: Non-mutated, safer TCRs due to high through-put automation process Natural TCRs are functionally expressed, folded, complexed Proprietary Transduce DCs with with other TCR components, Target antigen in vitro DC antigen-encoding mRNA and delivered to surface membrane at appropri
Slide 10: Targetable tumor-specific antigens in non-coding regions: cancer's dark matter
Targetable immunogenic tumor-specific antigens in non- coding regions of the genome – cancer’s ‘dark matter’ In normal cells, non-exomic regions (‘dark matter’) are not transcribed. In cancer cells, some ‘dark matter’ is transcribed and can be recognized by TCRs Peptides presented by tumors but not
Slide 11: Tumor specific dark matter antigens are immunogenic and recognized by TCR-T cells
Tumor specific ‘dark matter’ antigens are immunogenic and recognized by TCR-T cells Among 47 candidates, 10 immunogenic TSAs were identified across 5 different HLA types B) TSA-specific TCR-T cells recognize A) Immunogenic TSAs can be identified TSA-expressing target cells HLA-A1 TCR HLA-A2 TCR HLA-
Slide 12: Addressing diversity: Multiple HLAs to cover world population
Addressing diversity: Multiple HLAs to cover world population • TCR-T products addressing five common HLA-A allotypes give broad population coverage • Commercial opportunity maximized with simple epitope-HLA combinations per target antigen Five HLA-A allotypes cover ~89% Multiple epitopes and HLA al
Slide 13: Enhanced TCR-Ts to address solid tumors
medigene Enhanced TCR-Ts to address solid tumors
Slide 14: Empowered T cells for hostile solid tumor microenvironment
Empowered T cells for hostile solid tumor microenvironment Co-stimulatory PD1-41BB switch receptor Hypo-active T cell Inhibition Impact on T cell T Inhibition C Exhaustion Tumor Tumor Apoptosis cell cell Overcoming inhibitory signals in the tumor milieu through Activation additional co-stimulation a
Slide 15: Expression of PD1-41BB in TCR-Ts improves repetitive killing capacity
Expression of PD1-41BB in TCR-Ts improves repetitive killing capacity TCR in vivo data for improved efficacy of next-generation PRAME-specific TCR with TCR PD1-41BB switch receptor expected Q2 2021 with switch • TCR-T cells expressing PD1-41BB – improved killing of PD-L1-positive tumor cells. • PD1-
Slide 16: MDG10XX – Medigene's next-generation TCR-T candidate
MDG10XX – Medigene’s next-generation TCR-T candidate PRAME-specific TCR-4 shows potent in vitro and in vivo anti-tumor reactivity and a favorable preclinical safety profile A C 1000 T cell injection Tumor volume [mm3] 4000 PRAME-positive PRAME-negative TCR-4 displays functional 800 3000 activity acr
Slide 17: Medigene's matrix approach
Medigene’s matrix approach Many TCRs combined with our tools result in many potential drug products used in different indications 17
Slide 18: Clinical data
medigene Clinical data
Slide 19: MDG1011 – TCR-Ts targeting blood cancer
MDG1011 – TCR-Ts targeting blood cancer ASH poster, 7 December 2020 Target antigen: PRAME (Preferentially Expressed Antigen in Melanoma) Other PRAME - well-characterized tumor antigen, expressed in many hematological and solid tumor indications Phase I/II study: Combined Phase I/II Study for safety,
Slide 20: DC vaccine – Phase I/II trial in AML completed
DC vaccine – Phase I/II trial in AML completed Deceased Very good safety and tolerability Deceased Surviving Very good feasibility of manufacturing the vaccine from monocytes of heavily chemotherapy-pretreated patients Topline results No serious adverse events 80% overall survival (even when differe
Slide 21: Validation & value creation with partnerships
medigene Validation & value creation with partnerships
Slide 22: Partnerships highlight value of Medigene's TCR-T platform
Partnerships highlight value of Medigene’s TCR-T platform bluebird bio Roivant / Cytovant TCR discovery projects for multiple antigen/HLA Preclinical-stage TCR specific for the target combinations NY-ESO-1; clinical indications chosen Worldwide development and commercial rights and DC vaccine progra
Slide 23: Financial outlook
Financial outlook FY 2020 Guidance 2021 Total revenues €8.8 m €7-9 m R&D expenses €22.3 m € -20 m EBITDA loss €22.2 m € 0-17 m Cash and cash equivalents as of 3 ec 2020 amounted to ~€30.0 m Runway – will fund business operations into Q3 2022 No milestone payments or cash inflows included from existi
Slide 24: Enhanced TCR-Ts for solid tumors
Enhanced TCR-Ts for solid tumors Cutting edge ability to select optimal T cell receptors Optimal TCR properties: Higher avidity and specificity Strength in screening healthy TCR repertoires: Improved safety Collection of TCRs against different antigens and HLAs Antigen targets of choice including un
Slide 25: Thank you — Q&A
medigene Thank you — Q&A
Slide 26: Contact
Contact Dr. Gary Waanders Dr. Anna Niedl VP Investor Relations Director Investor Relations g.waanders@medigene.com a.niedl@medigene.com +49 89 2000 3333 01 +49 89 2000 3333 01 Medigene AG T +49 89 2000 33 0 Lochhamer Str. 11 F +49 89 2000 33 2920 82152 Planegg / Martinsried investor@medigene.com Ger